申请人:Ma Zhenkun
公开号:US20050261262A1
公开(公告)日:2005-11-24
Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.
本发明涉及具有抗微生物活性的利福霉素衍生物,包括对耐药微生物的活性。本发明的利福霉素衍生物独特地设计在于,它们具有利福霉素基团通过利福霉素基团的C-3碳与连接基团共价连接,并且连接基团进一步与治疗性基团或抗菌剂/药效团共价连接。治疗性基团可以是喹诺酮、噁唑烷酮、大环内酯、氨基糖苷、四环素核心或与抗菌剂相关的结构/药效团。